Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 10/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713954 | 1.00 | ERBB2 (0.40) | ERBB2KDREPHA2EPHB4CHEK1 | |
| SCHEMBL1613257 | 1.00 | ERBB2 (0.40) | ERBB2KDREPHA2EPHB4CHEK1 | |
| SCHEMBL1612854 | 0.94 | SRC (0.43) | ERBB2KDRCHEK1EGFRATR | |
| SCHEMBL1611632 | 0.80 | BCL6 (0.47) | BCL6ALKINSR | |
| SCHEMBL1612972 | 0.79 | SRC (0.45) | ERBB2KDREPHA2EPHB4CHEK1 | |
| SCHEMBL1825928 | 0.78 | LRRK2 (0.45) | CHEK1ATRSRCALKINSR | |
| SCHEMBL12743916 | 0.78 | ERBB2 (0.35) | ERBB2KDREPHA2EPHB4CHEK1 | |
| SCHEMBL12743544 | 0.78 | MAP3K14 (0.46) | ERBB2KDREPHA2EPHB4CHEK1 | |
| SCHEMBL12743907 | 0.78 | MAP3K14 (0.46) | ERBB2KDREPHA2EPHB4CHEK1 | |
| SCHEMBL12743228 | 0.77 | SRC (0.39) | KDRCHEK1EGFRSRCBCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | ERBB2 336/4885KDR 1011/4885EPHA2 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.